Navigation Links
SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM)
Date:4/8/2009

HOUSTON, April 8 /PRNewswire/ -- LaserGen, Inc., a DNA sequencing technology company, announced a definitive agreement in which SeqWright Inc. will make an equity investment in the company. Prompting its decision was LaserGen's recently revealed plans to commercialize its novel reversible terminator chemistry, Lightning Terminators(TM), for next-generation sequencing applications. The company anticipates bringing its chemistry as reagent kits to the market as early as 2010, by forming strategic partnerships with existing next-generation instrument manufacturers. SeqWright's investment and next-generation sequencing expertise are expected to facilitate LaserGen's effort in achieving that goal. Financial terms of the transaction were not disclosed.

The superior kinetics and natural DNA restoration of Lightning Terminators(TM) inform the promise of increased speed, throughput, and read-length, while lowering cost. These benefits are achieved through LaserGen's nucleotide chemistry by attaching a special terminating group directly to the base, freeing up the critical 3'-hydroxyl group. These Lightning Terminators(TM) exhibit excellent enzymatic properties with commercially available DNA polymerases. In kinetic terms, Lightning Terminators(TM) are more efficient than natural nucleotides, a measure of how fast they are added by and how well they bind to DNA polymerase. Simply stated, Lightning Terminators(TM) are better than nature. All reversible terminators required a cleavage step to remove the terminating and fluorescent dye groups. Upon cleavage, however, Lightning Terminators(TM) restore the incorporated nucleotide back to its natural state. This distinguishes the LaserGen chemistry from other reversible terminators, which leave accumulating molecular scars as the DNA strand propagates.

The decision to invest in LaserGen represents SeqWright's ongoing initiative to support the development of and build upon its previous investments in next-generation sequencing technologies. As a large-scale provider of DNA sequencing services, SeqWright is ideally suited to invest in next-generation technologies by providing equity investment, testing and validation. "We are very pleased to support LaserGen in their efforts," says Dr. Fei Lu, M.D., CEO of SeqWright Inc., "to advance the state of DNA sequencing, and we are excited about the savings in both, time and cost, which we expect their technologies to generate."

About LaserGen

LaserGen, Inc. is an early-stage nucleic acids chemistry company, founded in 2002. The company has been funded through NIH-sponsored small business and research grants to develop a variety of innovative technologies for next-generation sequencing applications. The SeqWright agreement marks LaserGen's transition from bench discoveries to market-ready technologies. Information about LaserGen, Inc. is available at www.lasergen.com

About SeqWright

SeqWright Inc. is a commercial provider of genomic analysis and molecular biology services. SeqWright has more than 15 years of experience specializing in state-of-the-art molecular biology and genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright, please visit www.seqwright.com.


'/>"/>
SOURCE SeqWright Inc.; LaserGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. California Grants SeqWright License to Operate as a Clinical Laboratory
2. SeqWright Expands Next Generation Lineup with the Addition of 454s GS FLX(TM) System
3. SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System
4. Voler Systems Continues Investments and Expands Services
5. Pharmaxis Investor Conference Call
6. Senetek PLC Announces New Investor Communication Hotline
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
9. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. Stallergenes : Investor Meeting: Webcast is Available
11. Accera, Inc. to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):